IOCB Prague and the Institute of Physiology have signed a license agreement with Novo Nordisk
31 August 2017
The Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), in collaboration with the Institute of Physiology of the CAS, have developed new compounds with positive effects in experimental animal models of obesity and type II diabetes.
Compounds were developed in the laboratory of Dr. Lenka Maletínská (IOCB Prague), whose team focused on the synthesis and the study of the modified analogues of endogenous neuropeptides.
Institutes have signed collaborative research and license agreements with the major pharmaceutical company, Novo Nordisk, which will develop and prepare these compounds for preclinical testing on animal models followed by clinical trials, if successful.
Read next...
